Har­vard prof Omid Farokhzad heads west, set­ting up a new Bay Area biotech on a mis­sion to start a rev­o­lu­tion in pre-symp­to­matic dis­ease de­tec­tion

As a Har­vard pro­fes­sor with close ties to MIT’s Bob Langer, Omid Farokhzad has en­joyed a high-pro­file role in the Boston/Cam­bridge biotech com­mu­ni­ty, where he’s par­tic­i­pat­ed in launch­ing a line­up of star­tups. And now Farokhzad — whose ac­com­plish­ments ex­tend to his role as physi­cian-sci­en­tist at Brigham and Women’s Hos­pi­tal — has put it all in his rear view mir­ror, jour­ney­ing out to the Bay Area to launch a new biotech he vows can go on to play a rev­o­lu­tion­ary role in open­ing the door to the ear­ly de­tec­tion of dis­eases.

And this time, he’s helm­ing the ven­ture as a first-time CEO.

The com­pa­ny is called Seer, which is tak­ing its place in the bustling biotech hub that Genen­tech helped cre­ate in South San Fran­cis­co. The big idea: Shift­ing away from ge­nomics, Seer’s team has been build­ing a pro­teomics plat­form that will do some pop­u­la­tion-wide ex­plo­rations, build­ing a moun­tain of da­ta that can be probed with ma­chine learn­ing tech in search of in­sights in­to dis­eases that can be used to de­vel­op liq­uid biop­sy prod­ucts for ear­ly-stage di­ag­no­sis.  

Bob Langer

The ear­li­er you are in de­tect­ing dis­ease, the bet­ter your chances of cur­ing it — or stop­ping it from be­com­ing a threat. If it works, Seer will build and mar­ket liq­uid biop­sy prod­ucts for pre-symp­to­matic dis­eases, start­ing with can­cer and neu­rol­o­gy.

Why the abrupt change of lo­cale and jobs? We talked about that.

“If I didn’t put my own fin­ger­print on (Seer) in a mean­ing­ful way,” Farokhzad tells me, “I knew I would re­gret it for the rest of my life.”

The Bay Area, he adds, is the on­ly place he can find the right tal­ent mix to do this com­plex tech work on the pro­teome, a dis­ci­pline that would re­quire ex­per­tise in nan­otech­nol­o­gy (his spe­cial­ty), pro­tein chem­istry, ma­chine learn­ing and da­ta an­a­lyt­ics for a mas­sive amount of da­ta — “done rapid­ly at scale.”

Hav­ing formed Seer a year ago, Farokhzad left his Cam­bridge/Boston post last March to join a team that has since grown to 20. Dur­ing that time, he’s pieced to­geth­er $36 mil­lion in ven­ture sup­port for his com­pa­ny. That group of back­ers in­cludes Mav­er­ick Ven­tures and In­vus.

Philip Ma

MIT’s pro­lif­ic Langer, who’s al­lied with his for­mer post­doc stu­dent on star­tups like Blend Ther­a­peu­tics — which lat­er re­tooled its tech and changed its name to Tarve­da — is in for the ride, lead­ing the sci­en­tif­ic ad­vi­so­ry group for Seer. And then there’s Philip Ma, the pres­i­dent and chief busi­ness de­vel­op­ment of­fi­cer. The ex-McK­in­sey part­ner set up the Dig­i­tal Health Tech­nolo­gies and Da­ta Sci­ences group at Bio­gen. The rest of the team — which will dou­ble in size over the next year — in­cludes a broad range of tal­ents.

Farokhzad be­lieves they should be po­si­tioned to start pro­duc­ing clin­i­cal read­outs from their de­vel­op­ment work in 2019 and 2020, with their first new prod­uct on the 2021 time hori­zon.

“Pre­clin­i­cal is tough to de­ci­pher,” says the sci­en­tist. “You have to get in­to clin­i­cal stud­ies to re­al­ly un­der­stand what’s go­ing on.”

The sci­en­tist has banked plen­ty of ex­pe­ri­ence along the way of an event­ful ca­reer. His list of star­tups in­cludes Se­lec­ta as well as Bind Bio­sciences, which sold off its as­sets un­der bank­rupt­cy.

At this point, the tech­nol­o­gy he’s now fo­cused on has reached the stage where you can do some­thing fast with a small num­ber of pro­teins, or take days and weeks to go broad. Farokhzad be­lieves Seer is po­si­tion­ing it­self to go broad fast, which could have ma­jor im­pli­ca­tions. Be­ing able at some point to re­li­ably iden­ti­fy pre-symp­to­matic Alzheimer’s, to use the most ob­vi­ous and chal­leng­ing ex­am­ple, would open up a new ap­proach to drug de­vel­op­ment af­ter bil­lions of dol­lars have been burned up in fruit­less R&D pro­grams.

Big dream? You could say so. If Il­lu­mi­na is the leader in ge­nomics, Farokhzad be­lieves the new­ly un­veiled Seer can be­come a gi­ant just as big fol­low­ing the pro­teomics path­way.

“There is an ex­treme­ly large vac­u­um to fill in be­com­ing a leader in this field,” he says. “We’re talk­ing about many tens of bil­lions of mar­ket op­por­tu­ni­ty.”


Im­age: Omid Farokhzad. SEER

Com­mu­ni­cat­ing the val­ue of pre­ci­sion med­i­cine

By Natasha Cowan, Content Marketing Manager at Blue Latitude Health.
Many stakeholders are confused by novel precision medicines, including patients and healthcare professionals. So, how can industry help them to navigate this complexity?

Precision medicine represents a new paradigm in healthcare. It embodies the shift from treating many patients with the same therapy, to having the tools to identify the best treatment for every patient.

Spe­cial re­port: Twen­ty ex­tra­or­di­nary women in bio­phar­ma R&D who worked their way to the top

What differentiates a woman leader in biopharma R&D from a man?

Not much, except there are fewer of them in senior posts. Data suggest women are not more risk-averse, family-oriented or less confident than their male counterparts — indeed the differences between the two sexes are negligible. But a glance at the top R&D positions in Big Pharma leaves little doubt that upward migration in the executive ranks of biopharma R&D is tough.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,300+ biopharma pros reading Endpoints daily — and it's free.

GSK's asth­ma bi­o­log­ic Nu­cala scores in rare blood dis­or­der study

GlaxoSmithKline’s asthma drug Nucala, which received a resounding FDA rejection for use in chronic obstructive pulmonary disease (COPD) last year, has shown promise in a rare blood disorder.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,300+ biopharma pros reading Endpoints daily — and it's free.

Mer­ck buys a fledg­ling neu­rode­gen­er­a­tive biotech spawned by an old GSK dis­cov­ery al­liance. What’s up with that?

Avalon Ventures chief Jay Lichter has a well-known yen for drug development programs picked up in academia. And what he found in Haoxing Xu’s lab at the University of Michigan pricked his interest enough to launch one of his umbrella biotechs in San Diego.
Xu’s work laid the foundation for Avalon to launch Calporta, which has been working on finding small molecule agonists of TRPML1 (transient receptor potential cation channel, mucolipin subfamily, member 1) for lysosomal storage disorders. And that pathway, they believe, points to new approaches on major market neurodegenerative diseases like Parkinson’s, ALS and Alzheimer’s.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,300+ biopharma pros reading Endpoints daily — and it's free.

FDA slaps a hold on an AML tri­al as Mark­er scraps a fail­ing ovar­i­an can­cer pro­gram, sink­ing shares

The FDA has placed a hold on a Phase II AML trial from the small immuno-oncology biotech Marker Therapeutics. Marker disclosed the issue two weeks after responding to FDA concerns, adding it to the Q3 release Tuesday. The company also announced it was scrapping a Phase II ovarian cancer program it determined was unlikely to succeed.

The agency’s concern centers around two reagents used in manufacturing for their trial for acute myeloid leukemia patients who have received a stem cell transplant. The reagents are from third parties and not present in the final product, Marker said.

Eli Lil­ly-backed biotech grabs $100M to dis­patch an­ti­body-oligonu­cleotide con­ju­gates af­ter mus­cu­lar dy­s­tro­phy

Hold up your hand. Make a fist. Now open it. And again.

If you can do it fully and with ease, then the proteins in your hand are likely working properly. If you can’t then they may not be. In people with myotonic muscular dystrophy, something more atomic is going on.

In those folks, the problem is RNA. Certain base pairs repeat far beyond normal, up to 11,000 superfluous letters in some cases. The extended strands form “clumps.” Proteins misform and can’t function properly. They often allow one movement but not the reverse, a condition called myotonia that gives the dystrophy its name.

As­traZeneca sets stage for mar­ket­ing ap­pli­ca­tion with promis­ing piv­otal lu­pus drug da­ta

After fumbling in its first late-stage lupus study, AstraZeneca disclosed that a second pivotal trial testing its experimental drug, anifrolumab, had met the main goal, in August. Earlier this week, the British drugmaker broke out the numbers from its successful study.

Last year, anifrolumab failed to meet the main goal of diminishing disease activity in the 460-patient TULIP I study, a 52-week trial that tested two doses of the drug versus a placebo. But in the 373-patient TULIP II study, the higher dose (300 mg) was compared to patients given a placebo — patients in both arms were on baseline standard care.

FDA Vas­cepa re­view spot­lights new safe­ty sig­nals, pos­si­ble min­er­al oil spoil­er as Amarin hunts a block­buster ap­proval

An in-house FDA review of Amarin’s Vascepa raises a set of hurdles the biotech will have to clear if the biotech expects to get the long-awaited FDA approval that could set it on a path to superstar status. But it appears that Amarin has survived another potential setback without introducing a major new threat to its prospects.

The stakes don’t get much higher, with analysts saying a win this week for Amarin could lead to billions in new sales — provided the agency stamps it with an OK. And investors liked what they say in the FDA review this morning, bumping the stock $AMRN 17%.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,300+ biopharma pros reading Endpoints daily — and it's free.

FDA puts Sol­id Bio’s lead gene ther­a­py pro­gram on hold — again — af­ter an­oth­er pa­tient is hurt by SGT-001

Solid Biosciences continues to be plagued by safety issues.

Close to 18 months after the gene therapy biotech was able to quickly shed an FDA hold on their lead Duchenne muscular dystrophy program for SGT-001, regulators have stepped back in to force another halt after another patient was hit hard by a set of serious adverse events remarkably similar to the first set.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,300+ biopharma pros reading Endpoints daily — and it's free.